ID   EGLN2_HUMAN             Reviewed;         407 AA.
AC   Q96KS0; A8K5S0; Q8WWY4; Q9BV14;
DT   16-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-JUN-2023, entry version 187.
DE   RecName: Full=Prolyl hydroxylase EGLN2 {ECO:0000305};
DE            EC=1.14.11.- {ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12039559, ECO:0000269|PubMed:15925519, ECO:0000269|PubMed:17114296, ECO:0000269|PubMed:23932902};
DE   AltName: Full=Egl nine homolog 2 {ECO:0000305};
DE            EC=1.14.11.29 {ECO:0000255|PROSITE-ProRule:PRU00805, ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12039559, ECO:0000269|PubMed:15925519};
DE   AltName: Full=Estrogen-induced tag 6 {ECO:0000303|PubMed:11850811};
DE            Short=EIT-6 {ECO:0000303|PubMed:11850811};
DE   AltName: Full=HPH-3;
DE   AltName: Full=Hypoxia-inducible factor prolyl hydroxylase 1;
DE            Short=HIF-PH1;
DE            Short=HIF-prolyl hydroxylase 1;
DE            Short=HPH-1;
DE   AltName: Full=Prolyl hydroxylase domain-containing protein 1 {ECO:0000303|PubMed:11595184};
DE            Short=PHD1 {ECO:0000303|PubMed:11595184};
GN   Name=EGLN2 {ECO:0000312|HGNC:HGNC:14660};
GN   Synonyms=EIT6 {ECO:0000303|PubMed:11850811};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P43).
RX   PubMed=11574160; DOI=10.1016/s0378-1119(01)00633-3;
RA   Taylor M.S.;
RT   "Characterization and comparative analysis of the EGLN gene family.";
RL   Gene 275:125-132(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P43), AND INDUCTION.
RC   TISSUE=Mammary cancer;
RX   PubMed=11850811; DOI=10.1038/sj.onc.1205113;
RA   Seth P., Krop I., Porter D., Polyak K.;
RT   "Novel estrogen and tamoxifen induced genes identified by SAGE (Serial
RT   Analysis of Gene Expression).";
RL   Oncogene 21:836-843(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM P43).
RC   TISSUE=Fetal brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM P43).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM P43).
RC   TISSUE=Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   REVIEW.
RX   PubMed=11595178; DOI=10.1016/s0092-8674(01)00518-9;
RA   Semenza G.L.;
RT   "HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the
RT   nucleus.";
RL   Cell 107:1-3(2001).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-358.
RX   PubMed=11595184; DOI=10.1016/s0092-8674(01)00507-4;
RA   Epstein A.C.R., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J.,
RA   Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M.,
RA   Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J.,
RA   Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J.;
RT   "C. elegans EGL-9 and mammalian homologs define a family of dioxygenases
RT   that regulate HIF by prolyl hydroxylation.";
RL   Cell 107:43-54(2001).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12163023; DOI=10.1016/s0006-291x(02)00862-8;
RA   Oehme F., Ellinghaus P., Kolkhof P., Smith T.J., Ramakrishnan S.,
RA   Huetter J., Schramm M., Flamme I.;
RT   "Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates
RT   activity of hypoxia-inducible transcription factors.";
RL   Biochem. Biophys. Res. Commun. 296:343-349(2002).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-297; ASP-299; HIS-358
RP   AND ARG-367.
RX   PubMed=12039559; DOI=10.1016/s0960-894x(02)00219-6;
RA   McNeill L.A., Hewitson K.S., Gleadle J.M., Horsfall L.E., Oldham N.J.,
RA   Maxwell P.H., Pugh C.W., Ratcliffe P.J., Schofield C.J.;
RT   "The use of dioxygen by HIF prolyl hydroxylase (PHD1).";
RL   Bioorg. Med. Chem. Lett. 12:1547-1550(2002).
RN   [12]
RP   FUNCTION, AND SUBSTRATE RECOGNITION MOTIF.
RX   PubMed=12181324; DOI=10.1074/jbc.m206955200;
RA   Huang J., Zhao Q., Mooney S.M., Lee F.S.;
RT   "Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation
RT   by the prolyl hydroxylases PHD1, PHD2, and PHD3.";
RL   J. Biol. Chem. 277:39792-39800(2002).
RN   [13]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=12615973; DOI=10.1242/jcs.00318;
RA   Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxsen J.H., Stolze I.,
RA   Klinger M., Huang W.Q., Wotzlaw C., Hellwig-Burgel T., Jelkmann W.,
RA   Acker H., Fandrey J.;
RT   "Intracellular localisation of human HIF-1 alpha hydroxylases: implications
RT   for oxygen sensing.";
RL   J. Cell Sci. 116:1319-1326(2003).
RN   [14]
RP   INDUCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=15247232; DOI=10.1074/jbc.m406026200;
RA   Appelhoff R.J., Tian Y.M., Raval R.R., Turley H., Harris A.L., Pugh C.W.,
RA   Ratcliffe P.J., Gleadle J.M.;
RT   "Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in
RT   the regulation of hypoxia-inducible factor.";
RL   J. Biol. Chem. 279:38458-38465(2004).
RN   [15]
RP   CATALYTIC ACTIVITY, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Liver;
RX   PubMed=15925519; DOI=10.1016/j.pep.2005.03.036;
RA   Cobb R.R., McClary J., Manzana W., Finster S., Larsen B., Blasko E.,
RA   Pearson J., Biancalana S., Kauser K., Bringmann P., Light D.R., Schirm S.;
RT   "Cloning and characterization of the rat HIF-1 alpha prolyl-4-hydroxylase-1
RT   gene.";
RL   Protein Expr. Purif. 42:295-304(2005).
RN   [16]
RP   FUNCTION, INTERACTION WITH SIAH2, ALTERNATIVE INITIATION, INDUCTION, AND
RP   MUTAGENESIS OF MET-1 AND MET-34.
RX   PubMed=16509823; DOI=10.1042/bj20051996;
RA   Tian Y.M., Mole D.R., Ratcliffe P.J., Gleadle J.M.;
RT   "Characterization of different isoforms of the HIF prolyl hydroxylase PHD1
RT   generated by alternative initiation.";
RL   Biochem. J. 397:179-186(2006).
RN   [17]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17114296; DOI=10.1073/pnas.0602235103;
RA   Cummins E.P., Berra E., Comerford K.M., Ginouves A., Fitzgerald K.T.,
RA   Seeballuck F., Godson C., Nielsen J.E., Moynagh P., Pouyssegur J.,
RA   Taylor C.T.;
RT   "Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving
RT   insight into hypoxia-induced NFkappaB activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18154-18159(2006).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19631610; DOI=10.1016/j.bbrc.2009.07.090;
RA   Steinhoff A., Pientka F.K., Mockel S., Kettelhake A., Hartmann E.,
RA   Kohler M., Depping R.;
RT   "Cellular oxygen sensing: Importins and exportins are mediators of
RT   intracellular localisation of prolyl-4-hydroxylases PHD1 and PHD2.";
RL   Biochem. Biophys. Res. Commun. 387:705-711(2009).
RN   [19]
RP   SUBCELLULAR LOCATION, FUNCTION, MOTIF, AND MUTAGENESIS OF LYS-102; ARG-106;
RP   ARG-113; ARG-119 AND ARG-134.
RX   PubMed=19339211; DOI=10.1016/j.bbamcr.2009.01.014;
RA   Yasumoto K., Kowata Y., Yoshida A., Torii S., Sogawa K.;
RT   "Role of the intracellular localization of HIF-prolyl hydroxylases.";
RL   Biochim. Biophys. Acta 1793:792-797(2009).
RN   [20]
RP   SUBSTRATE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21410436; DOI=10.1042/bj20101201;
RA   Pappalardi M.B., McNulty D.E., Martin J.D., Fisher K.E., Jiang Y.,
RA   Burns M.C., Zhao H., Ho T., Sweitzer S., Schwartz B., Annan R.S.,
RA   Copeland R.A., Tummino P.J., Luo L.;
RT   "Biochemical characterization of human HIF hydroxylases using HIF protein
RT   substrates that contain all three hydroxylation sites.";
RL   Biochem. J. 436:363-369(2011).
RN   [21]
RP   INTERACTION WITH LIMD1; WTIP AND AJUBA.
RX   PubMed=22286099; DOI=10.1038/ncb2424;
RA   Foxler D.E., Bridge K.S., James V., Webb T.M., Mee M., Wong S.C., Feng Y.,
RA   Constantin-Teodosiu D., Petursdottir T.E., Bjornsson J., Ingvarsson S.,
RA   Ratcliffe P.J., Longmore G.D., Sharp T.V.;
RT   "The LIMD1 protein bridges an association between the prolyl hydroxylases
RT   and VHL to repress HIF-1 activity.";
RL   Nat. Cell Biol. 14:201-208(2012).
RN   [22]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23932902; DOI=10.1016/j.devcel.2013.06.014;
RA   Moser S.C., Bensaddek D., Ortmann B., Maure J.F., Mudie S., Blow J.J.,
RA   Lamond A.I., Swedlow J.R., Rocha S.;
RT   "PHD1 links cell-cycle progression to oxygen sensing through hydroxylation
RT   of the centrosomal protein Cep192.";
RL   Dev. Cell 26:381-392(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24] {ECO:0007744|PDB:5V1B}
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 167-403 IN COMPLEX WITH INHIBITOR
RP   AND IRON, AND COFACTOR.
RX   PubMed=28594552; DOI=10.1021/acs.jmedchem.7b00352;
RA   Ahmed S., Ayscough A., Barker G.R., Canning H.E., Davenport R., Downham R.,
RA   Harrison D., Jenkins K., Kinsella N., Livermore D.G., Wright S.,
RA   Ivetac A.D., Skene R., Wilkens S.J., Webster N.A., Hendrick A.G.;
RT   "1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1)
RT   Inhibitors With a Novel Monodentate Binding Interaction.";
RL   J. Med. Chem. 60:5663-5672(2017).
CC   -!- FUNCTION: Prolyl hydroxylase that mediates hydroxylation of proline
CC       residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A
CC       (PubMed:11595184, PubMed:12039559, PubMed:15925519, PubMed:16509823,
CC       PubMed:17114296, PubMed:23932902). Target proteins are preferentially
CC       recognized via a LXXLAP motif (PubMed:11595184, PubMed:12039559,
CC       PubMed:15925519). Cellular oxygen sensor that catalyzes, under normoxic
CC       conditions, the post-translational formation of 4-hydroxyproline in
CC       hypoxia-inducible factor (HIF) alpha proteins (PubMed:11595184,
CC       PubMed:12039559, PubMed:12181324, PubMed:15925519, PubMed:19339211).
CC       Hydroxylates a specific proline found in each of the oxygen-dependent
CC       degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of
CC       HIF1A (PubMed:11595184, PubMed:12039559, PubMed:12181324,
CC       PubMed:15925519). Also hydroxylates HIF2A (PubMed:11595184,
CC       PubMed:12039559, PubMed:15925519). Has a preference for the CODD site
CC       for both HIF1A and HIF2A (PubMed:11595184, PubMed:12039559,
CC       PubMed:15925519). Hydroxylated HIFs are then targeted for proteasomal
CC       degradation via the von Hippel-Lindau ubiquitination complex
CC       (PubMed:11595184, PubMed:12039559, PubMed:15925519). Under hypoxic
CC       conditions, the hydroxylation reaction is attenuated allowing HIFs to
CC       escape degradation resulting in their translocation to the nucleus,
CC       heterodimerization with HIF1B, and increased expression of hypoxy-
CC       inducible genes (PubMed:11595184, PubMed:12039559, PubMed:15925519).
CC       EGLN2 is involved in regulating hypoxia tolerance and apoptosis in
CC       cardiac and skeletal muscle (PubMed:11595184, PubMed:12039559,
CC       PubMed:15925519). Also regulates susceptibility to normoxic oxidative
CC       neuronal death (PubMed:11595184, PubMed:12039559, PubMed:15925519).
CC       Links oxygen sensing to cell cycle and primary cilia formation by
CC       hydroxylating the critical centrosome component CEP192 which promotes
CC       its ubiquitination and subsequent proteasomal degradation
CC       (PubMed:23932902). Hydroxylates IKBKB, mediating NF-kappa-B activation
CC       in hypoxic conditions (PubMed:17114296). Also mediates hydroxylation of
CC       ATF4, leading to decreased protein stability of ATF4 (By similarity).
CC       {ECO:0000250|UniProtKB:Q91YE2, ECO:0000269|PubMed:11595184,
CC       ECO:0000269|PubMed:12039559, ECO:0000269|PubMed:12181324,
CC       ECO:0000269|PubMed:15925519, ECO:0000269|PubMed:16509823,
CC       ECO:0000269|PubMed:17114296, ECO:0000269|PubMed:19339211,
CC       ECO:0000269|PubMed:23932902}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + L-prolyl-[protein] + O2 = CO2 + succinate +
CC         trans-4-hydroxy-L-prolyl-[protein]; Xref=Rhea:RHEA:63484, Rhea:RHEA-
CC         COMP:12408, Rhea:RHEA-COMP:16354, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:16810, ChEBI:CHEBI:30031,
CC         ChEBI:CHEBI:50342, ChEBI:CHEBI:61965;
CC         Evidence={ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12039559,
CC         ECO:0000269|PubMed:15925519, ECO:0000269|PubMed:17114296,
CC         ECO:0000269|PubMed:23932902};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63485;
CC         Evidence={ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12039559,
CC         ECO:0000269|PubMed:15925519, ECO:0000269|PubMed:17114296,
CC         ECO:0000269|PubMed:23932902};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + L-prolyl-[hypoxia-inducible factor alpha
CC         subunit] + O2 = CO2 + succinate + trans-4-hydroxy-L-prolyl-[hypoxia-
CC         inducible factor alpha subunit]; Xref=Rhea:RHEA:48400, Rhea:RHEA-
CC         COMP:12093, Rhea:RHEA-COMP:12094, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:16810, ChEBI:CHEBI:30031,
CC         ChEBI:CHEBI:50342, ChEBI:CHEBI:61965; EC=1.14.11.29;
CC         Evidence={ECO:0000269|PubMed:11595184, ECO:0000269|PubMed:12039559,
CC         ECO:0000269|PubMed:15925519};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00805, ECO:0000269|PubMed:15925519,
CC         ECO:0000269|PubMed:28594552, ECO:0007744|PDB:5V1B};
CC       Note=Binds 1 Fe(2+) ion per subunit. {ECO:0000255|PROSITE-
CC       ProRule:PRU00805, ECO:0000269|PubMed:15925519,
CC       ECO:0000269|PubMed:28594552, ECO:0007744|PDB:5V1B};
CC   -!- COFACTOR:
CC       Name=L-ascorbate; Xref=ChEBI:CHEBI:38290;
CC         Evidence={ECO:0000269|PubMed:15925519};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=20 uM for HIF1A DLDLEMLAPYIPMDDDFQL peptide (at pH 7.5 and 37
CC         degrees Celsius) {ECO:0000269|PubMed:15925519};
CC         KM=50 uM for L-ascorbate (at pH 7.5 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15925519};
CC         KM=1 uM for Fe(2+) (at pH 7.5 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15925519};
CC   -!- SUBUNIT: Interacts (preferably isoform p40) with SIAH2; the interaction
CC       targets both SIAH2 isoforms for proteasomal degradation in vitro
CC       (PubMed:16509823). Interacts with LIMD1, WTIP and AJUBA
CC       (PubMed:22286099). {ECO:0000269|PubMed:16509823,
CC       ECO:0000269|PubMed:22286099}.
CC   -!- INTERACTION:
CC       Q96KS0; Q16665: HIF1A; NbExp=2; IntAct=EBI-726614, EBI-447269;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12163023,
CC       ECO:0000269|PubMed:12615973, ECO:0000269|PubMed:19339211,
CC       ECO:0000269|PubMed:19631610}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=p43; Synonyms=PHD1p43;
CC         IsoId=Q96KS0-1; Sequence=Displayed;
CC       Name=p40; Synonyms=PHD1p40;
CC         IsoId=Q96KS0-2; Sequence=VSP_038836;
CC   -!- TISSUE SPECIFICITY: Expressed in adult and fetal heart, brain, liver,
CC       lung, skeletal muscle, and kidney. Also expressed in testis and
CC       placenta. Highest levels in adult brain, placenta, lung, kidney, and
CC       testis. Expressed in hormone responsive tissues, including normal and
CC       cancerous mammary, ovarian and prostate epithelium.
CC       {ECO:0000269|PubMed:12163023}.
CC   -!- INDUCTION: By estrogen (PubMed:11850811). Induced by proteasomal
CC       inhibitor MG132 (at protein level) (PubMed:16509823).
CC       {ECO:0000269|PubMed:11850811, ECO:0000269|PubMed:16509823}.
CC   -!- INDUCTION: [Isoform p43]: Induced by hypoxia leading to protein
CC       stability. {ECO:0000269|PubMed:15247232}.
CC   -!- INDUCTION: [Isoform p40]: Repressed by hypoxia.
CC       {ECO:0000269|PubMed:15247232}.
CC   -!- DOMAIN: The Beta(2)beta(3) 'finger-like' loop domain is important for
CC       substrate (HIFs' CODD/NODD) selectivity.
CC       {ECO:0000250|UniProtKB:Q9GZT9}.
CC   -!- PTM: Ubiquitinated by SIAH1 and/or SIAH2 in response to the unfolded
CC       protein response (UPR), leading to its degradation.
CC       {ECO:0000250|UniProtKB:Q91YE2}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH01723.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ310544; CAC42510.1; -; mRNA.
DR   EMBL; AY040565; AAK82943.1; -; mRNA.
DR   EMBL; AK291385; BAF84074.1; -; mRNA.
DR   EMBL; AL832506; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC008537; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471126; EAW57008.1; -; Genomic_DNA.
DR   EMBL; BC001723; AAH01723.1; ALT_INIT; mRNA.
DR   EMBL; BC036051; AAH36051.1; -; mRNA.
DR   CCDS; CCDS12567.1; -. [Q96KS0-1]
DR   RefSeq; NP_444274.1; NM_053046.3. [Q96KS0-1]
DR   RefSeq; NP_542770.2; NM_080732.3. [Q96KS0-1]
DR   PDB; 5V1B; X-ray; 2.49 A; A=167-403.
DR   PDBsum; 5V1B; -.
DR   AlphaFoldDB; Q96KS0; -.
DR   SMR; Q96KS0; -.
DR   BioGRID; 125184; 37.
DR   CORUM; Q96KS0; -.
DR   IntAct; Q96KS0; 8.
DR   MINT; Q96KS0; -.
DR   STRING; 9606.ENSP00000469686; -.
DR   BindingDB; Q96KS0; -.
DR   ChEMBL; CHEMBL3028; -.
DR   DrugBank; DB00126; Ascorbic acid.
DR   DrugBank; DB11682; Daprodustat.
DR   DrugBank; DB04847; Roxadustat.
DR   DrugBank; DB12255; Vadadustat.
DR   DrugCentral; Q96KS0; -.
DR   GuidetoPHARMACOLOGY; 2832; -.
DR   GlyGen; Q96KS0; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96KS0; -.
DR   PhosphoSitePlus; Q96KS0; -.
DR   BioMuta; EGLN2; -.
DR   DMDM; 32129513; -.
DR   MassIVE; Q96KS0; -.
DR   MaxQB; Q96KS0; -.
DR   PaxDb; Q96KS0; -.
DR   PeptideAtlas; Q96KS0; -.
DR   ProteomicsDB; 77112; -. [Q96KS0-1]
DR   ProteomicsDB; 77113; -. [Q96KS0-2]
DR   Antibodypedia; 66726; 475 antibodies from 32 providers.
DR   DNASU; 112398; -.
DR   Ensembl; ENST00000303961.9; ENSP00000307080.3; ENSG00000269858.6. [Q96KS0-1]
DR   Ensembl; ENST00000406058.6; ENSP00000385253.1; ENSG00000269858.6. [Q96KS0-1]
DR   Ensembl; ENST00000593726.5; ENSP00000469686.1; ENSG00000269858.6. [Q96KS0-1]
DR   GeneID; 112398; -.
DR   KEGG; hsa:112398; -.
DR   MANE-Select; ENST00000303961.9; ENSP00000307080.3; NM_080732.4; NP_542770.2.
DR   UCSC; uc002opg.5; human. [Q96KS0-1]
DR   AGR; HGNC:14660; -.
DR   CTD; 112398; -.
DR   DisGeNET; 112398; -.
DR   GeneCards; EGLN2; -.
DR   HGNC; HGNC:14660; EGLN2.
DR   HPA; ENSG00000269858; Low tissue specificity.
DR   MIM; 606424; gene.
DR   neXtProt; NX_Q96KS0; -.
DR   OpenTargets; ENSG00000269858; -.
DR   PharmGKB; PA27671; -.
DR   VEuPathDB; HostDB:ENSG00000269858; -.
DR   eggNOG; KOG3710; Eukaryota.
DR   GeneTree; ENSGT00940000160655; -.
DR   HOGENOM; CLU_063064_0_0_1; -.
DR   InParanoid; Q96KS0; -.
DR   OMA; SSKRPWA; -.
DR   OrthoDB; 5358684at2759; -.
DR   PhylomeDB; Q96KS0; -.
DR   TreeFam; TF314595; -.
DR   BioCyc; MetaCyc:ENSG00000171570-MON; -.
DR   BRENDA; 1.14.11.2; 2681.
DR   BRENDA; 1.14.11.29; 2681.
DR   PathwayCommons; Q96KS0; -.
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   SignaLink; Q96KS0; -.
DR   SIGNOR; Q96KS0; -.
DR   BioGRID-ORCS; 112398; 159 hits in 1166 CRISPR screens.
DR   GeneWiki; EGLN2; -.
DR   GenomeRNAi; 112398; -.
DR   Pharos; Q96KS0; Tclin.
DR   PRO; PR:Q96KS0; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q96KS0; protein.
DR   Bgee; ENSG00000269858; Expressed in left testis and 96 other tissues.
DR   ExpressionAtlas; Q96KS0; baseline and differential.
DR   Genevisible; Q96KS0; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016706; F:2-oxoglutarate-dependent dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:UniProtKB.
DR   GO; GO:0031418; F:L-ascorbic acid binding; IEA:UniProtKB-KW.
DR   GO; GO:0019826; F:oxygen sensor activity; IDA:UniProtKB.
DR   GO; GO:0031545; F:peptidyl-proline 4-dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0045454; P:cell redox homeostasis; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IBA:GO_Central.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0018401; P:peptidyl-proline hydroxylation to 4-hydroxy-L-proline; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   Gene3D; 2.60.120.620; q2cbj1_9rhob like domain; 1.
DR   InterPro; IPR005123; Oxoglu/Fe-dep_dioxygenase.
DR   InterPro; IPR006620; Pro_4_hyd_alph.
DR   InterPro; IPR044862; Pro_4_hyd_alph_FE2OG_OXY.
DR   PANTHER; PTHR12907; EGL NINE HOMOLOG-RELATED; 1.
DR   PANTHER; PTHR12907:SF6; PROLYL HYDROXYLASE EGLN2; 1.
DR   Pfam; PF13640; 2OG-FeII_Oxy_3; 1.
DR   SMART; SM00702; P4Hc; 1.
DR   PROSITE; PS51471; FE2OG_OXY; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Dioxygenase; Iron; Metal-binding;
KW   Nucleus; Oxidoreductase; Phosphoprotein; Reference proteome;
KW   Ubl conjugation; Vitamin C.
FT   CHAIN           1..407
FT                   /note="Prolyl hydroxylase EGLN2"
FT                   /id="PRO_0000206664"
FT   DOMAIN          278..376
FT                   /note="Fe2OG dioxygenase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00805"
FT   REGION          1..34
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          50..89
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          108..157
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          225..235
FT                   /note="Beta(2)beta(3) 'finger-like' loop"
FT                   /evidence="ECO:0000250|UniProtKB:Q9GZT9"
FT   MOTIF           89..134
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   COMPBIAS        1..19
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        60..77
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         297
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00805,
FT                   ECO:0000269|PubMed:28594552, ECO:0000312|PDB:5V1B"
FT   BINDING         299
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00805,
FT                   ECO:0000269|PubMed:28594552, ECO:0000312|PDB:5V1B"
FT   BINDING         358
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00805,
FT                   ECO:0000269|PubMed:28594552, ECO:0000312|PDB:5V1B"
FT   BINDING         367
FT                   /ligand="2-oxoglutarate"
FT                   /ligand_id="ChEBI:CHEBI:16810"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00805"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..33
FT                   /note="Missing (in isoform p40)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038836"
FT   MUTAGEN         1
FT                   /note="M->A: Leads to expression of isoform p40 only."
FT                   /evidence="ECO:0000269|PubMed:16509823"
FT   MUTAGEN         34
FT                   /note="M->A: Leads to expression of isoform p43 only."
FT                   /evidence="ECO:0000269|PubMed:16509823"
FT   MUTAGEN         102
FT                   /note="K->A: Retained in the nucleus."
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   MUTAGEN         106
FT                   /note="R->A: Retained in the nucleus."
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   MUTAGEN         113
FT                   /note="R->A: Retained in the nucleus."
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   MUTAGEN         119
FT                   /note="R->A: Cytoplasmic and nuclear localization. Reduced
FT                   transcriptional activity of HIF1A as for wild type."
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   MUTAGEN         134
FT                   /note="R->A: Retained in the nucleus."
FT                   /evidence="ECO:0000269|PubMed:19339211"
FT   MUTAGEN         297
FT                   /note="H->A: Eliminates hydroxylase activity."
FT                   /evidence="ECO:0000269|PubMed:12039559"
FT   MUTAGEN         299
FT                   /note="D->A: Eliminates hydroxylase activity."
FT                   /evidence="ECO:0000269|PubMed:12039559"
FT   MUTAGEN         358
FT                   /note="H->A: Eliminates hydroxylase activity."
FT                   /evidence="ECO:0000269|PubMed:11595184,
FT                   ECO:0000269|PubMed:12039559"
FT   MUTAGEN         367
FT                   /note="R->A: Eliminates hydroxylase activity."
FT                   /evidence="ECO:0000269|PubMed:12039559"
FT   MUTAGEN         367
FT                   /note="R->K: Eliminates hydroxylase activity on a HIF1A
FT                   peptide."
FT                   /evidence="ECO:0000269|PubMed:12039559"
FT   CONFLICT        176
FT                   /note="R -> P (in Ref. 2; AAK82943)"
FT                   /evidence="ECO:0000305"
FT   HELIX           173..180
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           182..188
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          190..195
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           199..215
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          239..243
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           251..265
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   TURN            266..269
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          270..273
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          282..287
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          294..297
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          305..313
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           320..323
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          327..329
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          332..335
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          346..351
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          358..360
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          363..365
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   STRAND          367..375
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           377..385
FT                   /evidence="ECO:0007829|PDB:5V1B"
FT   HELIX           392..395
FT                   /evidence="ECO:0007829|PDB:5V1B"
SQ   SEQUENCE   407 AA;  43650 MW;  F172E9B0482C9CF3 CRC64;
     MDSPCQPQPL SQALPQLPGS SSEPLEPEPG RARMGVESYL PCPLLPSYHC PGVPSEASAG
     SGTPRATATS TTASPLRDGF GGQDGGELRP LQSEGAAALV TKGCQRLAAQ GARPEAPKRK
     WAEDGGDAPS PSKRPWARQE NQEAEREGGM SCSCSSGSGE ASAGLMEEAL PSAPERLALD
     YIVPCMRYYG ICVKDSFLGA ALGGRVLAEV EALKRGGRLR DGQLVSQRAI PPRSIRGDQI
     AWVEGHEPGC RSIGALMAHV DAVIRHCAGR LGSYVINGRT KAMVACYPGN GLGYVRHVDN
     PHGDGRCITC IYYLNQNWDV KVHGGLLQIF PEGRPVVANI EPLFDRLLIF WSDRRNPHEV
     KPAYATRYAI TVWYFDAKER AAAKDKYQLA SGQKGVQVPV SQPPTPT
//
